Paul Fiorilli, MD
Interventional Cardiology · Philadelphia, PANPI 1194040436
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Edwards Lifesciences accounts for 72.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $39,132 and has fallen 66.8% since, to $12,986 in 2025. Among interventional cardiology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 278 payments — averaging $374.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$75K
- Medtronic$20K
- Abbott$3K
- C. R. Bard, Inc. & Subsidiaries$2K
- Abiomed$1K
- Boston Scientific$682
- plus $2K from 14 others
Across 6 payments — averaging $5187.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- W. L. Gore & Associates, Inc.$18K
- Medtronic$11K
- Abbott$2K
What the payments were for
- Consulting fees$54,65653%
- Speaking & faculty fees$19,76019%
- Travel & lodging$17,23717%
- Food & beverage$12,26612%
- Gifts$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 98 | $75,000 |
| Medtronic(2 entities) | 63 | $19,651 |
| Abbott | 31 | $3,168 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $2,310 |
| Abiomed | 40 | $1,042 |
| Boston Scientific | 9 | $682 |
| Shockwave Medical, Inc | 10 | $540 |
| Terumo Medical Corporation | 4 | $508 |
| W. L. Gore & Associates, Inc. | 6 | $332 |
| Biotronik Inc. | 1 | $165 |
| AstraZeneca | 1 | $106 |
| Johnson & Johnson | 1 | $100 |
| Stryker | 2 | $83 |
| Chiesi USA, Inc. | 1 | $75 |
| Cathworks, Inc. | 3 | $67 |
| Philips North America LLC | 1 | $50 |
| Teleflex LLC | 2 | $38 |
| Amgen | 1 | $27 |
| Atricure, Inc. | 1 | $27 |
| Inari Medical, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$46,138
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$24,121
- COREVALVE EVOLUT R$15,205
- CoreValve Evolut$3,456
- TRICLIP$1,315
- SAPIEN 3 Ultra RESILIA$834
- MitraClip$503
- Impella$389
- NAVITOR$300
- AVVIGO Guidance System$221
- SYMPLICITY G3$174
- Orsiro Mission$165
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$160
- GENERAL - STRUCTURAL HEART$148
- AMPLATZER Occluders$133
- GORE CARDIOFORM Septal Occluder$125
- PASCAL$120
- GENERAL CATHETER$116
How this compares
$103,995 in reported general payments places this provider in the 90th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 13 | $452 |
| Metoprolol Succinate | 29 | $423 |
| Atorvastatin Calcium | 32 | $396 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 18 | $327 |
| Amlodipine Besylate | 40 | $290 |
| Ezetimibe | 14 | $215 |
| Losartan Potassium | 11 | $90 |
| Furosemide | 11 | $87 |
| Carvedilol | 18 | $82 |
| Hydrochlorothiazide | 16 | $76 |
| Fenofibrate | 14 | $55 |
| Lisinopril | 12 | $33 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Philadelphia
- Jon GeorgePhiladelphia$637K
- Sanjog KalraPhiladelphia$444K
- Taisei KobayashiPhiladelphia$384K
- Howard HerrmannPhiladelphia$259K
- Jay GiriPhiladelphia$157K
- Nicholas RuggieroPhiladelphia$74K
- Craig FrankilPhiladelphia$59K
- Michael BodePhiladelphia$58K
- Oleg VishnevskyPhiladelphia$49K
- Ashwin NathanPhiladelphia$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.